{"id":"ad-237","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1165764","moleculeType":"Protein","molecularWeight":"1056.23"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Adenosine A2A receptor antagonism reduces the immunosuppressive effects of adenosine on T cells and natural killer cells, thereby enhancing anti-tumor immune responses. This mechanism is intended to work synergistically with checkpoint inhibitors or as a monotherapy to reinvigorate anti-tumor immunity in the tumor microenvironment.","oneSentence":"AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:19:04.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT00242333","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD","status":"COMPLETED","sponsor":"Sosei","startDate":"2005-10","conditions":"COPD","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AD 237","genericName":"AD 237","companyName":"Sosei","companyId":"sosei","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment. Used for Advanced solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}